TMT. Minor

T. Minor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


T. Minor has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lebertransplantation in Deutschland

    by M. Wolff, J. C. Kalff, N. T. Schwarz, H. Lauschke, T. Minor, R. H. Tolba, A. Hirner

    Das wesentliche Problem der Lebertransplantation (LT) in Deutschland wie auch in anderen westlichen Ländern ist die Diskrepanz zwischen der steigenden Zahl von Patienten auf der nationalen Warteliste und der stagnierenden Zahl verfügbarer Organe hirntoter Spender. Das Problem des Sterbens von Patienten auf der Warteliste ist offenkundig geworden seit Umsetzung des Transplantationsgesetzes, das eine patientenorientierte im Unterschied zur früheren Zentrums-orientierten Organallokation vorsieht und neben der medizinischen Dringlichkeit die Wartezeit als wesentliches Kriterium anwendet. Die liberalere Akzeptanz so genannter marginaler Spenderlebern kann die Ergebnisse der LT nicht verbessern. Durch neuere Techniken kann der Spendermangel teilweise kompensiert werden. Hierzu gehören die Teilung von Spenderlebern (Splitting) für zwei Erwachsene oder einen Erwachsenen und ein Kind. Eine weitere Alternative ist die Lebendspende von Leberteilen, die zunächst für Kinder entwickelt wurde, neuerdings aber auch in steigendem Umfang zur Versorgung von erwachsenen Empfängern eingesetzt wird. Im Jahr 2001 wurde eine relativ konstante Zahl von 757 Lebertransplantationen in Deutschland durchgeführt, hiervon ein steigender Anteil von 12,5 % Lebendspenden. Richtlinien zur Indikation und Meldung von Patienten mit chronischem oder akutem Leberversagen sind kürzlich von der Bundesärztekammer publiziert worden. Neuere Entwicklungen, die zu einer Verbesserung der Ergebnisse nach LT geführt haben, sind neben operationstechnischen Details Fortschritte in einer individuell angepassten Immunsuppression und Vermeidung eines Rezidivs bei viral bedingter Grundkrankheit. As in other western countries the major challenge of liver transplantation in Germany is to expand the number of liver transplantations in respect to the increasing disparity of qualified patients on the waiting list and the still static availability of brain death donor organs. The problem of death on the waiting list has become overt since the German transplantation law has been installed, which has changed the former center-oriented to a patient-oriented allocation weighting waiting time over medical urgency criteria. The more liberal acceptance of so called marginal cadaveric donor livers will probably impair further improvements in the acute and long-term outcome of liver transplantation. This problem can be partially compensated by the use of novel surgical techniques, such as splitting a donor liver to be transplanted into two adult recipients or, more commonly and safe, into an adult and one child. Another alternative to increase the donor pool is living donor liver transplantation, which was first introduced for pediatric recipients but is now increasingly used in adults. In 2001, a constant number of 757 liver transplantations were performed in Germany, including 12.5 % living donor transplantations. Recently, general guidelines for the selection of patients with end-stage liver disease and acute liver failure have been published by the Bundesärztekammer. Additional developments have contributed to improve the results of liver replacement including individualized immunosuppression strategies and novel treatment options to avoid recurrent viral disease following transplantation.


  • Value of α glutathione S-transferase for in vitro evaluation of preservation injury in normal and steatotic livers

    by T. Minor, S. Akbar, R. Tolba

    Liver steatosis is frequently encountered at organ harvest and, although functionally inapparent in the donor, may seriously affect the functional recovery of the graft after ischemic preservation. The present study was aimed to investigate the diagnostic value of alpha-glutathione S-transferase (GST) in non-ischemic and ischemic livers with or without compensated steatosis. A histologically documented mild to moderate steatosis was induced in livers of male Wistar rats by fasting for 2 days and subsequent feeding of a fat-free diet enriched in carbohydrates. Fatty livers (FL) were retrieved and perfused in vitro for 45 min either immediately or after ischemic preservation at 4 degrees C in HTK solution. Effluate was collected during isolated perfusion and later analysed for liver specific enzymes, including GST. Normal livers (NL) were excised from healthy rats and underwent the same protocol. Non-ischemic livers showed similar enzyme release (FL versus NL) for ALT or GLDH but significant differences in GST. After ischemic preservation of NL, enzyme release increased mildly with respect to the non-ischemic reference values for ALT, remained unchanged for GLDH and rose substantially for GST. In FL, there was a more than 10-fold increase in all parameters, being most pronounced for GLDH as a marker of mitochondrial damage. It is concluded that GST may discriminate between healthy and suboptimal steatotic livers prior to ischemia and that the release of GST upon postischemic reperfusion of normal livers proves to be the most sensitive indicator for hepatocellular injury. However, GST turned out to be less useful for the detection of postischemic reperfusion injury in steatotic grafts.